Pharmatek, founded in 1999, offers dosage form development and clinical-scale cGMP manufacturing of oral, injectable and topical products for over 100 customers globally. The acquisition will add discovery-to-clinic
US biopharmaceutical firm Exelixis discovered and developed Cabometyx, which is claimed to be the first and only therapy approved in the European Union to demonstrate enhanced overall survival,
The company conducted the trial on 233 patients at 18 sites in Germany, who were randomized to receive one or two doses of FMX013 (3% or 1.5% minocyline
Sirukumab is a human monoclonal IgG1 kappa antibody that targets the cytokine IL-6, a naturally occurring protein that is thought to play a role in autoimmune conditions such
Based in Cambridge of Massachusetts, the new company will develop new comprehensive solutions which will include devices, software, medicine and professional care for diabetes management. The new JV
The government confirmed 11 new cases of the locally-transmitted virus including one case linked to the Elite Terrace cluster. The other ten cases have no known links to
The company is currently evaluating OV101 in the STARS study, a randomized, double-blind, placebo-controlled Phase 2 trial designed to explore the efficacy endpoints and assess the safety parameters
The company is developing the drug with Spanish pharmaceutical firm Ferrer. It has now recruited 130 patients from 11 clinical sites across three European countries. The trial, which
Sparsentan was tested on 109 patients with FSGS, which is a rare kidney disorder that leads to end-stage renal disease. Patients treated with 200, 400 and 800 mg/day
The agency's action date (PDUFA) is 24 December 2016. Merck has filed a marketing application in Europe for the similar indication. The data supporting the submissions was generated
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.